Osteoporosis Tx Ups Survival in Postmenopausal Breast Cancer

This article originally appeared here.
Share this content:
Osteoporosis Tx Ups Survival in Postmenopausal Breast Cancer
Osteoporosis Tx Ups Survival in Postmenopausal Breast Cancer

MONDAY, May 8, 2017 (HealthDay News) -- For postmenopausal breast cancer patients receiving aromatase inhibitors, oral osteoporosis therapy (OPT) is associated with improved survival, according to a study published online May 2 in Cancer.

Allan Lipton, M.D., from the Penn State Hershey Medical Center, and colleagues enrolled 7,576 postmenopausal women in the MA.27 phase 3 adjuvant trial. Patients were permitted bisphosphonates to prevent or treat osteopenia/osteoporosis and were followed for event-free and distant disease-free survival (EFS and DDFS).

The researchers found that osteoporosis was reported by 654 women (8.6 percent) at baseline and by 1,294 women in total. At baseline, oral OPT was received by 10.8 percent of the women and by 36 percent in total. There were 693 EFS events (9.15 percent) and 321 DDFS events (4.2 percent) during a median follow-up of 4.1 years. There was no correlation noted for EFS or DDFS with osteoporosis. There were few EFS events before OPT initiation, with no substantial evidence of a time-differing effect on outcomes. OPT correlated with improved EFS and DDFS (hazard ratios for yes versus no, 0.67 and 0.57, respectively). There was no association for time-differing OPT with EFS. There was no correlation for OPT with incidence of visceral-only metastasis.

"Oral OPT, administered to postmenopausal breast cancer patients receiving adjuvant aromatase inhibitor therapy, was associated with improved EFS and DDFS; the time of OPT initiation (a time-dependent effect) did not affect the outcome," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Surveillance Frequency Doesn't Cut Mortality in Colorectal Cancer

Surveillance Frequency Doesn't Cut Mortality in Colorectal Cancer

And, intensity of imaging surveillance not linked to time to detection of colorectal cancer recurrence

Procalcitonin Assay Doesn't Cut Antibiotic Use in Lower RTI

Procalcitonin Assay Doesn't Cut Antibiotic Use in Lower ...

Provision of assay doesn't result in less antibiotic use for suspected lower respiratory tract infection

Preventing Child Maltreatment Not Yet Feasible in Primary Care

Preventing Child Maltreatment Not Yet Feasible in Primary ...

USPSTF says evidence inadequate for primary care interventions to prevent child maltreatment

is free, fast, and customized just for you!

Already a member?

Sign In Now »